波生坦水合物 T6265

Product Introduction
Bioactivity


英文名: Bosentan (hydrate)

描述: Bosentan hydrate (Ro 47-0203) 是endothelin-1 (ET)竞争性拮抗剂，在人SMC 细胞中，它能够作用于 ETA 受体(Ki:4.7 nM)和 ETB 受体(Ki:95 nM)。

细胞实验: Bosentan is prepared in DMSO and diluted with appropriate medium before use[2]. Cell viability is evaluated by the trypan blue exclusion test. Human dermal fibroblasts are treated with the indicated concentration of Bosentan (10, 20 and 40 μM). Cell viability is examined at 24 and 48 hours. Stained (dead) and unstained (viable) cells are counted with a hematocytometer[2].

体外活性: Bosentan competitively antagonizes the specific binding of [125 I]-labeled ET-1 on human smooth muscle cells (ET-A receptors)human placenta (ET-B receptors). Bosentan also inhibits the binding of selective ET-B ligands on porcine trachea. Contractions induced by ET-1 in isolated rat aorta (ET-A) and by the selective ET-B agonist sarafotoxin S6C in rat trachea are competitively inhibited by Bosentan (pA2= 7.2 and 6.0, respectively), as is the endothelium-dependent relaxation to sarafotoxin S6C in rabbit superior mesenteric artery (pA2= 6.7). The binding of 40 other peptides, prostaglandins, ions and neurotransmitters is not significantly affected by Bosentan, which shows its specificity for ET receptors. [1]

体内活性: Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity. Bosentan also inhibits the depressor and presser effect of ET-1 and sarafotoxin S6C. Its pharmacological profile makes Bosentan a potentially useful drug in the management of clinical disorders associated with vasoconstriction.[1] Bosentan is the first oral non-peptide mixed ETA/B-receptor antagonist. Long-term treatment with Bosentan has markedly increased the survival, hemodynamics, and cardiac remodeling in rats with CHF. Bosentan decreases arterial BP to a similar degree as an angiotensin-converting enzyme (ACE) inhibitor. Administration of Bosentan in rats with CHF after acute MI significantly decreases arterial BP and has additive effect to that of an ACE inhibitor. Acute and chronical treatment with Bosentan also improves the systemic and pulmonary hemodynamics by a decrease in peripheral and pulmonary vascular resistance, and increase of cardiac output in patients with CHF. [2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 93 mg/mL (163.3 mM)
Ethanol : 2 mg/mL (3.51 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)


关键字: Bosentan (hydrate) | Endothelin Receptor | Bosentan | inhibit | Inhibitor

相关产品: Macitentan | Endothelin 1 (swine, human) acetate | Atrasentan hydrochloride | Darusentan | BQ-788 | Aprocitentan | Atrial natriuretic peptide (3-28) (human) | Patecibart | Ro 46-2005 | Sitaxsentan

相关库: Drug Repurposing Compound Library | Anti-Hypertension Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Human Metabolite Library | GPCR Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library

波生坦水合物 T6265信息由TargetMol中国为您提供，如您想了解更多关于波生坦水合物 T6265报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途